Production (Stage)
Stoke Therapeutics, Inc.
STOK
$9.18
-$0.18-1.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 158.57M | 22.61M | 4.89M | 4.83M | 4.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 158.57M | 22.61M | 4.89M | 4.83M | 4.22M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 158.57M | 22.61M | 4.89M | 4.83M | 4.22M |
| SG&A Expenses | 14.65M | 12.84M | 12.69M | 13.04M | 10.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.33M | 36.27M | 34.90M | 34.17M | 32.59M |
| Operating Income | 111.24M | -13.65M | -30.00M | -29.34M | -28.37M |
| Income Before Tax | 114.16M | -10.48M | -26.43M | -25.70M | -26.37M |
| Income Tax Expenses | 1.28M | -- | -- | -- | -- |
| Earnings from Continuing Operations | 112.88M | -10.48M | -26.43M | -25.70M | -26.37M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 112.88M | -10.48M | -26.43M | -25.70M | -26.37M |
| EBIT | 111.24M | -13.65M | -30.00M | -29.34M | -28.37M |
| EBITDA | 111.72M | -13.13M | -29.46M | -28.79M | -27.81M |
| EPS Basic | 1.95 | -0.18 | -0.47 | -0.46 | -0.57 |
| Normalized Basic EPS | 1.23 | -0.11 | -0.29 | -0.29 | -0.36 |
| EPS Diluted | 1.90 | -0.18 | -0.47 | -0.46 | -0.57 |
| Normalized Diluted EPS | 1.20 | -0.11 | -0.29 | -0.29 | -0.36 |
| Average Basic Shares Outstanding | 57.86M | 57.03M | 56.34M | 55.77M | 46.25M |
| Average Diluted Shares Outstanding | 59.40M | 57.03M | 56.34M | 55.77M | 46.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |